Anodyne Nanotech

Anodyne Nanotech is a Boston-based biotechnology company that develops differentiated transdermal forms of high-value drugs through its proprietary Hero Patch platform. The platform utilizes microneedle technology invented at Tufts University to deliver clinically meaningful doses of macromolecules and small molecules. By incorporating solvent-free bulk drug substances directly into microscopic porosities, Anodyne can load unprecedented amounts of drugs onto each microneedle. When the microneedle penetrates the skin, the drug dissolves in the patient's interstitial fluid and gets systemically absorbed.

This technique allows for higher drug loading compared to traditional transdermal patches while also potentially improving drug stability by using the solid-state form, circumventing the need for cold-chain distribution. Anodyne's primary focus is on delivering biologics, particularly monoclonal antibodies and peptides, with successful in vivo delivery demonstrated.

In May 2021, Anodyne raised USD 4.2 million in seed funding from Velocity Partners, Relativity healthcare Fund, and Big Pi Ventures to expand its Hero Patch platform. The company has initiated collaborations with pharmaceutical firms to test specific biologics on the platform and plans to conduct clinical trials to characterize bioequivalence, safety, and tolerability of its products.